Literature DB >> 63236

Radioimmunoassays for prostaglandin metabolites.

E Granström, H Kindahl.   

Abstract

Radioimmunoassays were developed for the main plasma and urinary metabolites of PGF2alpha in the human, viz., 15-keto-13,14-dihydro-PGF2alpha and 5alpha, 7alpha-dihydroxy-11-ketotetranorprosta-1,16-dioic acid. The methods allowed assay of unextracted samples and had a sensitivity of 5 pg and 2 pg, respectively. The assays were evaluated by comparison with mass spectrometric data. Normal levels of these metabolites were estimated in a number of subjects. Levels in plasma and urine of the metabolites were followed after injection or during infusion of PGF2alpha and during administration of various antiinflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63236

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Res        ISSN: 0361-5952


  5 in total

1.  Differential effects of prostaglandin E2 and cyclic AMP on release of arachidonic acid metabolites from resting and lipopolysaccharide-stimulated macrophages.

Authors:  N Feuerstein; P W Ramwell
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

2.  Prostaglandin F2 alpha metabolite levels in normal and uterine-infected postpartum cows.

Authors:  F N Thompson; R D Page; C B Cook; A B Caudle
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

3.  In vivo and in vitro effects of endotoxin on prostaglandin release from rat lung.

Authors:  N Feuerstein; P W Ramwell
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

4.  Leukotrienes C4 and D4 induce prostaglandin and thromboxane release from rat peritoneal macrophages.

Authors:  N Feuerstein; M Foegh; P W Ramwell
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

5.  5'-Nucleotidase activity and arachidonate metabolism in doxorubicin sensitive and resistant P388 cells.

Authors:  A Ramu; D Glaubiger; P Soprey; G H Reaman; N Feuerstein
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.